SP
BravenNow
Ambrose, Vertex Pharmaceuticals SVP, sells $108k in VRTX stock
| USA | economy | ✓ Verified - investing.com

Ambrose, Vertex Pharmaceuticals SVP, sells $108k in VRTX stock

#Vertex Pharmaceuticals #VRTX stock #Insider trading #Biotechnology #Financial results #Analyst ratings #Stock valuation

📌 Key Takeaways

  • Kristen Ambrose sold $108k in Vertex stock under a pre-approved trading plan
  • Vertex reported Q4 revenue slightly above expectations despite a minor EPS miss
  • Analysts remain optimistic, raising price targets for the biotech company
  • The stock trades at a premium with a P/E ratio of 31.29

📖 Full Retelling

Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals (NASDAQ:VRTX), sold $108,456 worth of company stock on February 25, 2026, as part of a pre-approved trading plan. The transaction involved 223 shares sold at $486.35 each, reducing her direct ownership in the biotechnology firm. This recent sale follows another transaction on February 24, 2026, when Ambrose disposed of 546 shares at $485.11, totaling $264,870. Despite these insider sales, Ambrose continues to hold a significant stake of 6,981 shares in Vertex Pharmaceuticals, which currently trades at $480.13 with a market capitalization of $121.97 billion. Vertex Pharmaceuticals reported fourth-quarter 2025 financial results showing revenue of $3.19 billion, slightly exceeding analysts' expectations of $3.18 billion, though earnings per share came in at $5.03, marginally below the projected $5.08. Despite this minor earnings miss, financial analysts remain optimistic about the company's prospects, with Cantor Fitzgerald raising its price target to $590 and Oppenheimer upgrading the stock to Outperform with a $540 target, citing promising developments in the company's renal pipeline candidates.

🏷️ Themes

Insider Trading, Biotechnology, Financial Markets

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
Biotechnology

Biotechnology

Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...

View Profile → Wikipedia ↗
Vertex Pharmaceuticals

Vertex Pharmaceuticals

American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three re...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain This is where Deutsche Bank sees silver prices ending the year Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Ambrose, Vertex Pharmaceuticals SVP, sells $108k in VRTX stock By Investing.com Insider Trading Published 02/26/2026, 09:41 PM Ambrose, Vertex Pharmaceuticals SVP, sells $108k in VRTX stock 0 VRTX -0.60% Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals (NASDAQ:VRTX) , sold 223 shares of common stock on February 25, 2026, at a price of $486.35, for a total value of $108,456. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a company-approved 10b5-1 trading plan established on August 8, 2025. In addition, on February 24, 2026, 546 shares were disposed of at a price of $485.11, for a total value of $264,870. Following the sale, Ambrose directly owns 6,981 shares of Vertex Pharmaceuticals. The stock currently trades at $480.13, giving the biotech giant a market capitalization of $121.97 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value—investors can explore similar opportunities on the Most Overvalued list .Despite the insider sale, Vertex maintains a "GREAT" financial health score and has delivered a strong 23.4% return over the past six months. The company trades at a P/E ratio of 31.29 and stands as a prominent player in the Biotechnology industry. For deeper insights, InvestingPro offers a comprehensive Pro Research Report on VRTX, one of 1,400+ US equities covered with expert analysis and actionable intelligence. In other recent news, Vertex Pharmaceuticals reported its fourth-quarter 2025 financial results, revealing revenue of $3.19 billion, which surpassed an...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine